Background-The inhibition of dipeptidyl peptidase-4 (DPP4) protects the heart from acute myocardial ischemia.
D
ipeptidyl peptidase-4 (DPP4), also known as cellsurface antigen CD26, is a 110-kDa type II integral membrane glycoprotein that exhibits protease activity and belongs to the prolyl oligopeptidase family. [1] [2] [3] A primary function of DPP4 is to truncate various bioactive molecules such as stromal cell-derived factor-1␣ (SDF-1␣) and glucagon-like peptide-1 (GLP-1), and several reports have suggested that DPP4 represents a subfamily of gelatinolytic serine proteases that selectively bind to denatured collagen 4, 5 ; hence, DPP4 modulates pathological conditions such as diabetes mellitus (DM), malignancy, and inflammation. DPP4 is widely distributed in mammalian tissues, including kidney, small intestine, liver, and heart tissues. 2 A soluble form of DPP4 (s-DPP4), present in the circulatory system and body fluids, is thought to result from the proteolytic cleavage of the membrane-bound form (m-DPP4). 3 The results of an early study using colorimetric enzyme histochemistry suggested that the DPP4 protease activity is localized in the venous capillary vessels of the heart 3, 6 ; however, investigations of the precise distribution of DPP4 in the heart and the immunohistochemical identification of the cell types involved have not been undertaken.
Clinical Perspective on p 1851
In recent preclinical studies, pleiotropic effects of DPP4 inhibition were demonstrated to reduce mortality and cardiac remodeling after myocardial infarction 7, 8 ; however, whether the pathophysiological role of DPP4 in chronic heart failure is independent of coronary artery disease remains unclear. Diastolic left ventricular (LV) dysfunction (DHF) is a feature of heart failure characterized by pathological cardiac remodeling such as LV hypertrophy and fibrosis induced by comorbidity such as pressure overload or DM. 9, 10 In addition, a role has been postulated for chronic ischemia, which gradually develops in response to a mismatch between the coronary vasculature and cardiomyocyte growth associated with pathological remodeling [11] [12] [13] ; however, the existence of a link between chronic ischemia and the pathogenesis of DHF remains uncertain.
This study aimed to clarify the role of DPP4 in cardiac remodeling and DHF using distinct rodent models of induced DM or pressure overload. Additionally, we examined whether peripheral venous DPP4 activity may correlate with several factors related to DHF with the goal of uncovering a potential role for DPP4 as a diagnostic or therapeutic target for DHF in humans.
Methods
A detailed description of the methods is provided in Methods in the online-only Data Supplement.
Animals
Male congenital DPP4-null Fischer 344 rats, their syngeneic counterparts, and Wistar rats were used in this study. DM was induced by streptozotocin, and pressure overload was generated by transaortic constriction (TAC).
Cardiac Function Analyses
Cardiac function in rodents was analyzed with an echocardiogram and cardiac catheterization.
In Situ Cardiac DPP4 Activity
Cardiac DPP4 proteolytic activities of rat and human heart specimens were detected by in situ colorimetry with Gly-Pro-NA used as the substrate.
In Vitro Cardiac and Plasma DPP4 Activity
The DPP4 activity in each heart tissue extract and in plasma was measured with the DPP4-Glo assay (Promega). , heart tissue from a DPP4-deficient rat [C, right; DPP4(Ϫ)], and a human heart (D). DPP4 positivity is shown in red. Scale barϭ50 m. E and F, In vitro DPP4 activity in rat heart extracts (E) and plasma specimens (F). *PϽ0.05; **PϽ0.01 (nϭ6 -7).
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Patient Selection
DHF was diagnosed with Doppler echocardiography on the basis of elevated values for the ratio of early mitral inflow to mitral annular velocity (E/eЈ) and the deceleration time of the early mitral inflow with concomitant plasma brain natriuretic peptide elevation. The circulating s-DPP4 activities of these patients were measured using blood samples from peripheral veins (PVs), the coronary sinus (CS), and the aortic root.
Statistical Analysis
Values are expressed as meanϮSD. The homogeneity of data variance was assessed with the F test (2 groups) and the Bartlett test (multiple groups). The mean values of 2 groups were compared by use of the Student t test (when the variance was homogeneous) or the Welch t test (for heterogeneous variance). Comparisons of multiple means were performed with ANOVA (for homogeneous variance) or the Wilcoxon rank-sum test (for heterogeneous variance) if indicated. All group comparisons were followed by the Bonferroni post hoc test. Pearson correlation coefficients were estimated for the association between DPP4 activity and other variables in humans. Values of PϽ0.05 were considered statistically significant.
Results

The Capillary Endothelium Expresses DPP4 in the Heart
Using a colorimetric procedure, previous reports suggested that the DPP4-active regions localize in capillary vessels. 3, 6, 14 We sought to identify the subtype of DPP4-expressing cells in heart using immunohistochemistry. DPP4-positive sites overlapped with sites expressing the panendothelial marker platelet endothelial cell adhesion molecule/CD31 ( Figure  1A ). Immunoblot analysis revealed the DPP4 expression in both cultured venous and microvascular endothelial cells ( Figure 1B) .
We next performed in situ colorimetric staining to assess m-DPP4 activity in heart sections of Fischer rats ( Figure 1C , left), their DPP4-null counterparts ( Figure 1C , right), and humans ( Figure 1D ). DPP4-positive regions were red in both rat and human heart specimens, and the pattern of the DPP4 positivity was consistent with the results obtained by immu- nohistochemistry ( Figure 1A ). We validated the specificity of the in situ DPP4 staining using an in vitro assay to detect the proteolytic activity of DPP4 in rat heart extracts ( Figure 1E ) and plasma specimens ( Figure 1F ).
Cardiac m-DPP4 Activity Is Elevated in the Diabetic Heart
DM exacerbates heart failure 15 and is associated with DHF 9 and coronary microangiopathy. 16, 17 We investigated whether DM influences cardiac m-DPP4 activity (Figure 2A and 2B). (Table 1) . DP(ϩ)/DM rats exhibited decreased dP/dtmin ( Figure 2D ) and increased ( Figure 2E ) and diastolic stiffness ( Figure 2F ), findings consistent with the prolonged deceleration time of the early mitral inflow and reduced E/A value measured by echocardiography ( Table 1) . Immunohistochemistry ( Figure 2G -2J) revealed that the car- diomyocyte surface area ( Figure 2H ) and vascularity ( Figure  2I and 2J) were reduced in the DP(ϩ)/DM rats. In contrast, DM had no influence on either cardiac function or histological remodeling in DP(Ϫ) rats. We further examined whether the reduced vascularity in DP(ϩ)/DM rats promoted myocardial hypoxia using pimonidazole ( Figure 2K ). DM increased pimonidazole-positive green spots in the myocardium (top right), which were absent in DP(Ϫ)/DM rats (bottom right).
As an additional measure of hypoxia, hypoxia-inducible factor-1␣ expression ( Figure 2L and 2M) was consistently higher in DP(ϩ)/DM rats than in their nondiabetic counterparts [DP(ϩ)/c]; however, this trend was absent in the DPP4-null groups [DP(Ϫ)/DM and DP(Ϫ)/c].
Elevated Cardiac DPP4 Activity Causes Impaired Angiogenesis and Fibrosis in Diabetes Mellitus
DPP4 truncates SDF-1␣, 2,7 inactivating its angiogenic potential. 18, 19 Accordingly, we hypothesized that the cardiac m-DPP4 activation observed in the DP(ϩ)/DM rats may suppress angiogenesis through the reduction of SDF-1␣. Because electropho- resis (Tricine-SDS-PAGE) cannot separate the DPP4-cleaved biologically inactive form of SDF-1␣ protein from intact SDF-1␣, 7, 20 we performed preliminary experiments ( Figure I in the online-only Data Supplement) 21 and found ELISA to be superior for the detection of biologically active SDF-1␣. The cardiac SDF-1␣ levels were reduced in DP(ϩ)/DM rats compared with DP(ϩ)/c rats, whereas these levels remained unchanged in DP(Ϫ)/DM rats ( Figure 3A) . The cardiac concentration of vascular endothelial growth factor 16, 17 was reduced independently of DPP4 deficiency ( Figure 3B ). SDF-1␣ activates Akt/endothelial nitric oxide synthase (eNOS) signaling, which is essential for angiogenesis mediated by the trafficking of endothelial progenitor cells. [22] [23] [24] We examined whether the cardiac SDF-1␣ gradient is related to Akt/eNOS signaling ( Figure 3C and Figure 
DPP4 Inhibition Reverses DM-Induced Cardiac Fibrosis via the Matrix Metalloproteinase-2/Tissue Inhibitor of Metalloproteinase-2 Axis
We examined the impact of DPP4 on cardiac remodeling ( Figure 3E-3H) . DP(ϩ)/DM rats exhibited increased interstitial fibrosis of the heart, as detected by picro-Sirius red staining, which was reversed in DP(Ϫ)/DM rats ( Figure 3E and 3F) . Real-time polymerase chain reaction analysis revealed a DPP4-dependent increase in the accumulation of collagen (collagen types 1 and 3) and matrix metalloproteinase-2 (MMP2) with a concomitant decline in the level of tissue inhibitor of metalloproteinase-2 (TIMP2) and an elevation of connective tissue growth factor (Figure V in the online-only Data Supplement) in DP(ϩ)/DM rats. The level of ␤-myosin heavy chain of DP(ϩ)/DM rats was reduced ( Figure 3H ), which was partially but significantly reversed in the DP(Ϫ)/DM counterparts. MMP9, TIMP1, brain natriuretic peptide, and atrial natriuretic peptide levels were elevated ( Figure 3G and 3H) in DP(ϩ)/DM rats independently of DPP4 activity.
The Pharmacological Inhibition of DPP4 Reverses Diabetic DHF
Small-molecule inhibitors of DPP4 are widely used to treat diabetic patients. 25 We examined whether vildagliptin could ameliorate DM-induced cardiac remodeling and DHF. We validated the inhibitory effect of vildagliptin on circulating DPP4 activity with an in vitro assay ( Figure VI in the onlineonly Data Supplement). Vildagliptin ameliorated the DMinduced DHF without affecting systolic LV function (Figure 4A  and 4B and Table 2 ) or the declines in cardiomyocyte surface area and vascularity induced by DM ( Figure 4C and 4D) . DM suppressed cardiac SDF-1␣ levels ( Figure 4E ) and Akt/eNOS phosphorylation levels ( Figure 4F and Figure VII in the onlineonly Data Supplement) with a concomitant increase in the level of hypoxia-inducible factor-1␣ ( Figure VIII in the online-only Data Supplement) and the MMP2/TIMP2 ratio ( Figure 4G ) and increased connective tissue growth factor levels ( Figure IX in the online-only Data Supplement); these changes were reversed in response to vildagliptin treatment.
DPP4 Inhibition Protects the Heart Against Nondiabetic Stress Independently of SDF-1␣-Mediated Angiogenesis
Pressure overload is nondiabetic intervention contributing to the development of DHF. 9, 26 We evaluated the effect of genetic DPP4 inhibition on DHF and cardiac remodeling induced by TAC ( Figures 5 and 6 and Table 3 ). Echocardiograms revealed DHF with LV hypertrophy and a mild systolic dysfunction in DP(ϩ)/TAC rats. The DP(Ϫ)/TAC group exhibited LV hypertrophy, but their cardiac function remained intact (Table 3 ). Both DP(ϩ)/TAC and DP(Ϫ)/TAC rats exhibited increases in cardiomyocyte surface area ( Figure  5B ) without reduced angiogenesis ( Figure 5C ), leading to a proportional decrease in vascular density ( Figure 5D ). Consistently, Akt/mammalian target of rapamycin phosphorylation levels were elevated in the TAC groups independently of DPP4 activity ( Figure 
DPP4 Inhibition Reverses Pressure Overload-Induced LV Dysfunction Through the GLP-1/cAMP Axis
Cardiac m-DPP4 activities ( Figure 6A and 6B) were reduced in DP(ϩ)/TAC rats both in situ and in vitro. We thus hypothesized whether local hypoxia induced by TAC may modulate endothelial DPP4 expression. Hypoxic treatment reduced the levels of DPP4 of cultured endothelial cells ( Figure 6C ). GLP-1 is an incretin 27, 28 that is cleaved by s-DPP4 2 and exhibits inotropic effects. 8,29 -31 We next hypothesized that the s-DPP4 activity may increase in response to pressure overload and that the resultant GLP-1 may contribute to the DPP4-mediated and SDF-1␣-independent amelioration of cardiac dysfunction in the TAC rats. s-DPP4 activity was increased in DP(ϩ)/TAC rats ( Figure 6D) , and their GLP-1 levels were decreased and were reversed in DP(Ϫ)/ TAC rats ( Figure 6E ). Because GLP-1 activity is mediated by cAMP, 27, 31 we measured cardiac cAMP levels in each group ( Figure 6F ). Cardiac cAMP concentrations were reduced in DP(ϩ)/TAC rats. We observed no changes in the cardiac cAMP concentrations in diabetic rats ( Figure XIV in the online-only Data Supplement). We then tested the impact of GLP-1 receptor activation on the pressure overload-induced cardiac dysfunction by administering the DPP4-resistant agonist exendin-4 using mouse TAC models ( Table I in 
The Peripheral Venous DPP4 Activity of DHF Patients Correlates With E/e and Increases With Comorbid DM
The CS plasma is used to assess the myocardial release of bioactive molecules. 32 We assumed that the CS plasma would be the best specimen in which to measure myocardiumderived s-DPP4 activity in human patients (Figure 7) . Considering the ethical limitations on the repeated collection of blood specimens by invasive cardiac catheterization, we evaluated whether s-DPP4 activity in the peripheral veins (PV) is correlated with that in the CS ( Figure 7A ). We found that s-DPP4 activity in the CS was positively associated with that observed in PVs. In contrast, the s-DPP4 activity in aortic arterial blood showed no correlation with the PV specimens ( Figure 7B) . The s-DPP4 activity of PV was positively correlated with E/eЈ ( Figure 7C and Tables 4 and 5 ). Comorbid DM increased s-DPP4 activity in both the PV ( Figure 7D ) and the CS ( Figure 7E ).
Discussion
Studies investigating DPP4 are very common in the fields of hematology, oncology, and diabetology 2, 33 ; however, little is known about the pathophysiological significance of DPP4 in chronic heart failure. Our study presents experimental evidence illuminating the regulatory roles of DPP4 in chronic heart failure as mediated by its distinct forms and substrates, ie, m-DPP4 for SDF-1␣ and presumably the MMP2/TIMP2 axis and s-DPP4 for GLP-1, which we validated in distinct rodent models (Figure 8 ). Local and systemic stresses presumably alter DPP4 activity via unknown mechanisms. 34, 35 In the present study, consistent with a previous report, 23 DM promoted the activation of m-DPP4, thereby reducing cardiac SDF-1␣ concentrations ( Figure 3A) and causing impaired angiogenesis, presumably via a reduction of CXCR4 ϩ /KDR ϩ endothelial progenitor cell homing to the heart ( Figure 3D and Figure III in the online-only Data Supplement). In contrast, cardiac m-DPP4 activity of TAC was reduced ( Figure 6A and 6B) with elevated cardiac SDF-1␣ levels ( Figure 5H ), suggesting that cardiac m-DPP4 activity may be a key determinant of cardiac angiogenesis by modulating the SDF-1␣ gradient in response to both diabetic and nondiabetic pathologies.
In contrast to that observed in DM, m-DPP4 activity was decreased in the pressure-overloaded heart ( Figure 6A and 6B), presumably as a result of the hypoxia-mediated decrease in the level of endothelial m-DPP4 protein ( Figure 6C ), which was unchanged by high glucose treatment (data not shown).
One possible explanation for this reduction in m-DPP4 has been suggested by the observation of Lamers et al 34 demonstrating the potential existence of regulatory system(s) for m-DPP4 release in response to pathological stimuli. In case of pressure overload, concomitant hypoxia may accelerate m-DPP4 release (in other words, the cleavage of m-DPP4) from the capillary endothelium of the heart. In addition, our data also suggest that the regulatory system(s) may be impaired in DM, leading to the resultant DPP4 activation and microvasculopathy. Table 4 . A, DPP4 activity in the coronary sinus (CS; vertical axis) was positively correlated with the DPP4 activity in the peripheral vein (PV; A) but not with that in the coronary artery (B) in patients with diastolic left-ventricular dysfunction (DHF; nϭ30). C, DPP4 activity was negatively correlated with diastolic function (E/eЈ, the ratio of early mitral inflow to mitral annular velocity). D and E, DPP4 activities of PV (D) and CS (E) in diabetic (black bar) and nondiabetic (white bar) patients with DHF. Data are shown as meanϮSD. *PϽ0.05; **PϽ0.01 (nϭ15 per each group).
Streptozotocin-induced DM has been associated with myocardial atrophy and increased interstitial fibrosis. 36 In addition, ample evidence indicates that streptozotocin rat hearts exhibit diastolic abnormalities; both impaired relaxation and increased stiffness occur in the absence of hypertrophy and precede by weeks the onset of systolic dysfunction. 36 However, the precise mechanism of the DM-induced maladaptive collagen metabolism remains unclear. We examined the impact of DPP4 on cardiac fibrosis in both diabetic ( Figures  3E-3G and 4G and Figure V in the online-only Data Supplement) and pressure-overload ( Figure 5K and 5L and Figure IX in the online-only Data Supplement) models. The diabetic heart exhibited an increase in interstitial fibrosis, which was reversed in the DPP4-null group (Figure 3E and  3F) . We next evaluated changes in collagen accumulation (types 1 and 3), collagen breakdown promoters (MMP2 and MMP9), and collagen breakdown inhibitors (TIMP1 and TIMP2). There are various regulators for collagen metabolism in pathological conditions (reviewed extensively elsewhere 37 ). In particular, clinical and experimental studies have reported the increased expression of MMP2 in diabetic subjects. [12] [13] [14] [15] MMP2 plays a primary role in the development of diabetic microvasculopathy (retinopathy) by enhancing MMP2 with a corresponding decrease in TIMP2 in endothelial cells. 15 Cardiac MMP2 transgenic mice display increased collagen accumulation and exhibit biventricular dilation and disruption of the myocardium. 16 In the present study, the trend of increasing MMP2 levels in the streptozotocin rat heart was consonant with the atrophic changes in cardiomyocytes; in contrast, we observed a decrease in MMP2 expression and a corresponding increase in TIMP2 in the TAC heart ( Figure  5L ). Our finding based on TAC models also supports previous reports that TIMP2 is upregulated in patients with pressure-overload cardiomyopathy. 17, 18 With regard to angiogenesis, MMP2 is known as a protease that degrades SDF1␣ 7 ; thus, the trend of MMP2 expression in both diabetic and TAC models is consistent with our results concerning cardiac SDF1␣ contents ( Figure 3A and Figure 5H ) and capillary density ( Figure 2I and Figure 5C ). DPP4 is a weak endopeptidase for denatured collagen, 4,5 preferentially degrading collagens I and III. Although further evaluation is required, the DPP4 dependency of the MMP2/TIMP2 axis observed in the diabetic heart may constitute a link to collagen metabolism mediated by DPP4 as an endopeptidase. Taken together, our results and the results of previous studies suggest that the MMP2/TIMP2 ratio should increase in a DPP4-dependent manner when cardiac remodeling tends toward atrophy, ie, under diabetic stress without insulin stimulus.
GLP-1 is an incretin 27, 28 that is easily cleaved by s-DPP4 in circulation. 2 GLP-1 exhibits positive-inotropic effects via the endocrine system, and the exogenous administration of its receptor agonists (eg, exendin-4) ameliorates heart failure in humans 29 and in animals. 8, 30, 31 DPP-4 is a principal determinant of the circulating level of bioactive GLP-1, 35, 38 suggesting that the balance between s-DPP4 and GLP-1 may affect LV contractility (Figure 8 ). In addition to intact GLP-1, the DHF indicates diastolic heart failure; DM, diabetes mellitus; BMI, body mass index; HbA 1C , hemoglobin A 1C BNP, brain natriuretic peptide; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; LVDd, end-diastolic left ventricular diameter; LVDs, end-systolic left ventricular diameter; LVPW, left ventricular posterior wall; IVST, interventricular septal thickness; LVESV, left ventricular end-systolic volume; EF, ejection fraction; LVEDP, left ventricular end-diastolic pressure; LVEDV, left ventricular end-diastolic volume; and DcT, deceleration time of the early mitral valve. See the online-only Data Supplement for definitions of parameters.
Data (meanϮSD) were obtained by *cardiac catheterization and †echocar-diography in HFPEF patients with DM (nϭ15) and without DM (nϭ15). DPP-4 -cleaved form, GLP-1 9 -36 amide, exerts cardioprotective effects in rodents through mechanisms distinct from those of intact GLP-1. 31 In the present study, we did not explore the difference between these cardioprotective molecules, and further investigation is necessary to address this question.
Conclusion
The present study highlights a novel pathophysiological role for DPP4 in chronic heart failure and raises the possibility of using DPP4 as a diagnostic surrogate or a therapeutic target for chronic heart failure. 
